Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Clinical Trial ID NCT00640471

Rank	Title	Journal	Year	PubWeight™‹?›
1	Anti-VEGF therapies in the clinic.	Cold Spring Harb Perspect Med	2012	1.20
2	Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy.	J Hematol Oncol	2012	1.01
3	Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?	Cancer Manag Res	2013	0.88
4	Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives.	World J Gastroenterol	2013	0.85
5	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.	Oncotarget	2010	0.84
6	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.	Ther Adv Med Oncol	2012	0.81
7	Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.	Br J Cancer	2011	0.80
8	Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer.	Onco Targets Ther	2012	0.78